|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4550 Montgomery Avenue |
Address2 | Suite 1100N |
| City | Bethesda |
State | MD |
Zip Code | 20814 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 60195-12
|
||||||||
|
6. House ID# 353460000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Joel Aurora, Attorney & Agent |
Date | 7/20/2026 5:55:30 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS
H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS
H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS
H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS
S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT
S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS
GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM
GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1
GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS
GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS)
GENERAL DISCUSSION ON DRUG PRICING REFORM
GENERAL DISCUSSION ON HEALTH COVERAGE REFORM
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION
CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS
PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK
CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MARY |
DWIGHT |
|
|
|
DAVID |
ELIN |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS
H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS
H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS
S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT
GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM
GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1
GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS
GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS)
GENERAL DISCUSSION ON DRUG PRICING REFORM
GENERAL DISCUSSION ON HEALTH COVERAGE REFORM
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION
CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS
CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION
GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS
S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS
GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29
FOLLOW UP ON ALTERNATIVE FUNDING PROGRAMS AND IMPORTATION OF DRUGS; CFF SENDS LETTER TO FDA AND CDER REGARDING A CITIZEN PETITION CONCERNING ALTERNATIVE FUNDING PROGRAMS (AFPS)
COMMENTS ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK; CFF SUBMITS COMMENTS TO THE FDA ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK, URGING A FLEXIBLE APPROACH TO SUPPORT THE DEVELOPMENT OF GENE EDITING AND OTHER THERAPIES FOR PEOPLE WITH ULTRA-RARE MUTATIONS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MARY |
DWIGHT |
|
|
|
DAVID |
ELIN |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM
GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1
GENERAL DISCUSSION ON HEALTH COVERAGE REFORM
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION
CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS
PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
GENERAL DISCUSSION ON DRUG PRICING REFORM
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |